When was Immuto Scientific founded?

Immuto Scientific was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Immuto Scientific located?

Immuto Scientific is headquartered in Madison, United States.

Who is the current CEO of Immuto Scientific?

Daniel Benjamin and Faraz Choudhury s of Immuto Scientific. Daniel Benjamin has also founded 1 company.

How many employees does Immuto Scientific have?

As of Dec 31, 2022, Immuto Scientific has 7 employees, reflecting a 134% year-over-year growth in headcount.

Is Immuto Scientific a funded company?

Immuto Scientific is a funded company, having raised a total of $2.3M across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2018.

When was the latest funding round of Immuto Scientific?

Immuto Scientific's latest funding was a $***** Seed round on Oct 12, 2021, with participation from 4 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $1.84B in funding in 2026 to date.

Where does Immuto Scientific rank among its competitors?

Immuto Scientific ranks 12th amongst 132 active competitors, of which 40 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Unnatural Products, which secured $45M in Mar, 2026.

Who are the top competitors of Immuto Scientific?

Immuto Scientific's top competitors include Biognosys, Seer and ProteinQure. Among them, Unnatural Products secured the most recent funding round in March, 2026.

Immuto Scientific - 2026 Company Profile, Team, Funding & Competitors

Immuto Scientific is a seed company based in Madison (United States), founded in 2018 by Daniel Benjamin, Daniel Benjamin and Faraz Choudhury. It operates as a Digital drug discovery tool for reserchers. Immuto Scientific has raised $2.3M in funding from Wisconsin Investment Partners. The company has 132 active competitors, including 40 funded and 13 that have exited. Its top competitors include companies like Biognosys, Seer and ProteinQure.

Key Metrics

Founded Year

2018

Location

Madison, United States

Stage

Seed

Total Funding

$2.3M in 3 rounds

Latest Funding Round

Seed, Oct 12, 2021, $*****

Investors

Wisconsin Investment Partners & 8 more

Ranked

12^th among 132 active competitors

Employee Count

7 as on Dec 31, 2022

Similar Companies

Biognosys & 162 more

View Immuto Scientific's full profile

Immuto Scientific has raised a total funding of $2.3M over 3 rounds. Its first funding round was on 2018. Its latest funding round was a Seed round on Oct 12, 2021 for $*****. 4 investors participated in its latest round. Immuto Scientific has 9 institutional investors.

Here is the list of recent funding rounds of Immuto Scientific:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 12, 2021	4682140	Seed	5180269	9568187	6464131	1228985
Sep 01, 2019	8501947	Grant (prize money)	7303238	7651918	7517755	HHS
2018	8238	Grant (prize money)	4481	5387	2479	Madworks

Access funding benchmarks and valuations. Sign up today!

View details of Immuto Scientific's funding rounds and investors

The founders of Immuto Scientific are Daniel Benjamin, Daniel Benjamin and Faraz Choudhury. Daniel Benjamin and Faraz Choudhury are the CEOs of Immuto Scientific.

Here are the details of Immuto Scientific's key team members:

Daniel Benjamin: Co-Founder, Chief Technology Officer of Immuto Scientific.
Daniel Benjamin: Co-Founder & CEO of Immuto Scientific.
Contact Info: 1 email address
Faraz Choudhury: Co-Founder & CEO of Immuto Scientific.
Contact Info: 1 email address

View details of Immuto Scientific's Founder profiles and Board Members

Immuto Scientific's employee count trend

Immuto Scientific has 7 employees as of Dec 22. The total employee count is 133.0% more than what it was in Dec 21. Here is Immuto Scientific's employee count trend over the years:

Employee count trend for Immuto Scientific

Uncover Immuto Scientific's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immuto Scientific include Biognosys, Seer and ProteinQure. Here is the list of Top 10 competitors of Immuto Scientific, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Zurcher Kantonalbank, Redalpine & 6 others	63/100
2nd	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	61/100
3rd	ProteinQure 2017, Toronto (Canada), Series A	Provider of computational protein drug design platform	$15M	Felicis Ventures, Government of Canada & 9 others	61/100
4th	Peptris 2019, Bengaluru (India), Series A	Provider of AI-based proteomic data analysis software for drug discovery	$9.17M	Speciale Invest, Indian Angel Network Fund ... & 46 others	60/100
5th	Peptone 2016, Amsterdam (Netherlands), Series A	Provider of an AI based protein analysis platform for research and development	$42.5M	F-Prime Capital, Bessemer Venture Partners ... & 6 others	60/100
6th	Unnatural Products 2016, Santa Cruz (United States), Series B	Developer of computational biology techniques platform to engineer peptides for undruggable targets	$83M	Artis Ventures, Merck Global Health Innovation Fund ... & 17 others	59/100
7th	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	Fifty Years, Two Bear Capital & 11 others	59/100
8th	Cyrus Biotechnology 2014, Seattle (United States), Series B	Developer of cloud-based protein-modelling software for drug discovery	$32M	Trinity Ventures, Agent Capital & 11 others	57/100
9th	ProteinSimple 2004, San Jose (United States), Acquired	Provider tools to help researchers with protein analysis	$94.3M	Lansing Brown Investments, Royal Bank of Canada ... & 10 others	57/100
10th	Atavistik 2021, Cambridge (United States), Series B	Developer of allosteric therapeutics for precision oncology and rare diseases	$260M	The Column Group, Nextech Invest & 3 others	57/100
12th	Immuto Scientific 2018, Madison (United States), Seed	Digital drug discovery tool for reserchers	$2.3M	WARF, Venture Management & 7 others	54/100